Current studentsExisting staffContact us
 

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines

Simple item page
dc.contributor.authorLu, L.
dc.contributor.authorKok, C.H.
dc.contributor.authorSaunders, V.
dc.contributor.authorWang, J.
dc.contributor.authorMcLean, J.
dc.contributor.authorHughes, T.P.
dc.contributor.authorWhite, D.L.
dc.contributor.authorWhite, D.L.
dc.date.issued2018
dc.description.abstractTKI resistance remains a major impediment to successful treatment of CML. In this study, we investigated the emerging modes of ponatinib resistance in TKI-naïve and dasatinib resistant BCR-ABL1+ cell lines. To investigate potential resistance mechanisms, ponatinib resistance was generated in BCR-ABL1+ cell-lines by long-term exposure to increasing concentrations of ponatinib. Two cell lines with prior dasatinib resistance demonstrated BCR-ABL1 kinase domain (KD) mutation(s) upon exposure to ponatinib. In one of these cell lines the T315I mutation had emerged during dasatinib exposure. When further cultured with ponatinib, the T315I mutation level and BCR-ABL1 mRNA expression level were increased. In the other cell line, compound mutations G250E/E255K developed with ponatinib exposure. In contrast, the ponatinib resistant cell lines that had no prior exposure to other TKIs (TKI-naïve) did not develop BCR-ABL1 KD mutations. Rather, both of these cell lines demonstrated Bcr-Abl-independent resistance via Axl overexpression. Axl, a receptor tyrosine kinase, has previously been associated with imatinib and nilotinib resistance. Ponatinib sensitivity was restored following Axl inhibition or shRNA-mediated-knockdown of Axl, suggesting that Axl was the primary driver of resistance and a potential target for therapy in this setting.
dc.description.statementofresponsibilityLiu Lu, Chung Hoow Kok, Verity Ann Saunders, Jueqiong Wang, Jennifer Anne McLean, Timothy Peter Hughes, and Deborah Lee White
dc.identifier.citationOncotarget, 2018; 9(78):34735-34747
dc.identifier.doi10.18632/oncotarget.26187
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.orcidKok, C.H. [0000-0002-3181-7852]
dc.identifier.orcidHughes, T.P. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.orcidWhite, D.L. [0000-0003-4844-333X]
dc.identifier.urihttp://hdl.handle.net/2440/121307
dc.language.isoen
dc.publisherImpact Journals
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1135949
dc.rightsCopyright: Lu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.source.urihttps://doi.org/10.18632/oncotarget.26187
dc.subjectChronic myeloid leukaemia; ponatinib resistance; Bcr-Abl+ cell lines; compound mutation; Axl
dc.titleModelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
dc.title.alternativeModelling ponatinib resistance in tyrosine kinase inhibitor-naive and dasatinib resistant BCR-ABL1+ cell lines
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_121307.pdf
Size:
3.43 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications